Correction: Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens

Ítems similars

• Long-Lasting Protection of Activity of Nucleoside Reverse Transcriptase Inhibitors and Protease Inhibitors (PIs) by Boosted PI Containing Regimens
  per: Scherrer, Alexandra U., et al.
  Publicat: (2012)
• Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens.
  per: Alexandra U Scherrer, et al.
  Publicat: (2012-01-01)
• Minor Protease Inhibitor Mutations at Baseline Do Not Increase the Risk for a Virological Failure in HIV-1 Subtype B Infected Patients
  per: Scherrer, Alexandra U., et al.
  Publicat: (2012)
• Adverse events of raltegravir and dolutegravir
  per: Elzi, Luigia, et al.
  Publicat: (2017)
• Adherence as a Predictor of the Development of Class-Specific Resistance Mutations: The Swiss HIV Cohort Study
  per: von Wyl, Viktor, et al.
  Publicat: (2013)